We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Could Help Identify Early Skin Cancer

By LabMedica International staff writers
Posted on 05 Sep 2017
Newly developed technology uses artificial intelligence (AI) to help detect melanoma skin cancer earlier than current methods and to help reduce the number of unnecessary biopsies. More...
The AI-based method employs machine-learning software to analyze images of skin lesions and to provide doctors with objective data on telltale biomarkers of melanoma.

"This could be a very powerful tool for skin cancer clinical decision support," said Alexander Wong, professor at University of Waterloo (Waterloo, ON, Canada), "The more interpretable information there is, the better the decisions are." Prof. Wong developed the technology in collaboration with Daniel Cho, former PhD student at Waterloo, David Clausi, professor at Waterloo, and Farzad Khalvati, adjunct professor at Waterloo and scientist at Sunnybrook.

Currently, dermatologists largely rely on subjective visual examinations of skin lesions (e.g. moles) to decide if patients should undergo biopsies to diagnose the disease. The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on visual appearance alone. In particular, changes in the concentration and distribution of eumelanin (gives color to skin) and hemoglobin are strong indicators of melanoma.

"There can be a huge lag-time before doctors even figure out what is going on with the patient," said Prof. Wong, "Our goal is to shorten that process." The AI system was trained using tens of thousands of skin images and their corresponding eumelanin and hemoglobin levels. It gives doctors objective information on lesion characteristics to help them identify or rule out melanoma before deciding if to take more invasive action. The technology could be available to doctors as early as 2018.

The research was recently presented at the 14th International Conference on Image Analysis and Recognition (ICIAR 2017, July 5-7, 2017, Montreal, Canada).

Related Links:
University of Waterloo


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Portable POCT Blood Gas Analyzer
BD100
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.